The disciplines of anaesthesia and clinical pharmacology are related in as much as both have a mutual interest in the safe and conservative use of drugs in man. Anaesthetists have effectively been practising rational therapeutics for many years and they have much to offer academic departments of clinical pharmacology in terms of teaching and research programmes. Similarly, the clinical pharmacologist can usefully contribute to anaesthetic training and research programmes in relation to aspects such as education, precise analytical methods, datahandling and clinical trial techniques. The inter-relationship of the two disciplines can be of mutual advantage and has the potential to provide a stronger basis for sound therapeutic practice.
INTRODUCTION
The last 30 years has seen an impressive increase in the ability of the biological sciences to influence the human organism in terms of a multiplicity of chemical interventions. One outcome of this scientific expertise has been the development of therapeutic agents for use in the management of disease in the community. However, the enormous clinical benefit of the bewildering array of new and potent drugs which have been introduced into the consumer markets of most nations of the world, has been tempered somewhat by the occurrence of therapeutic disasters and by the increasing complexity of the modern therapeutic armamentarium. In order to translate the scientific advances which have been achieved into safe and effective therapy for people with diseasestates, it is necessary for the clinician to place much greater emphasis on the rational use of therapeutic agents.
The discipline of clinical pharmacology has arisen in recent years in response to the educational, clinical and research needs of modern drug therapy. Whilst clinical pharmacology has met with considerable (albeit variable) success in countries such as the United States, Britain and Canada (Proceedings of the first Symposium of Merck International Fellows in Clinical Pharmacology 1973), progress in Australia has been less rapid and of limited extent. The recent decision of the Australian Government, however, to progressively establish departments of clinical pharmacology over a period of about seven years in all Australian universities with medical schools (Leading Article 1975) , should now provide a firm base upon which strong and viable units can be built. Universities Commission finance will be employed for the venture which had been jointly proposed by the Australian Department of Health and the Australian Universities Com-mISSIOn.
In many respects, clinical pharmacology constitutes a diverse, multidisciplinary field; one in which appropriate pharmacological expertise can be offered to a number of clinical specialties. In addition, a number of clinical specialties may make a significant contribution to the practice of clinical pharmacology. It is with these thoughts in mind that this communication explores and outlines the potential rapport between the disciplines of anaesthesia and clinical pharmacology.
DEFINITION OF CLINICAL PHARMACOLOGY AND THE CLINICAL PHARMACOLOGIST
Clinical pharmacology is difficult to define. In broad terms, it is the scientific study of drugs L. B. JELLETT A:'ID T. E. OH in man (\\'HO report] 970). In particular, it is the study of rational, safe and effective usage of drugs in day to day medical practice. The clinical pharmacologist as an entity, may range from the drug-orientated clinician to the person who has undergone dual training in pharmacology and in a clinical specialty. The latter individual (Lasagna 1966) , is therefore well versed in basic pharmacological principles and is also competent clinically to care for patients at the consultant level.
The first prerequisite therefore for the clinical pharmacologist in the pure sense, is that he must have consultant status, so that Fellowship of the College of Physicians or one of its subspecialties is an essential requirement. It is vital to retain credibility in the wards by taking a good measure of responsibility for direct patient care. The clinical pharmacologist must be seen to be a competent clinician so that his comments about therapeutics are made in the context of an in depth understanding of the patient's clinical state. The second prerequisite must be a thorough training in both basic and clinical pharmacology, preferably with a B.Sc., :\I.D. or Ph.D. degree emphasizing various aspects of pharmacology. The training period should ideally include appropriate experience at a reputable school of clinical pharmacology. Scientific knowledge gained should range from an understanding of some aspects of physical chemistry, for example, drug absorption to plastic or glass, to the concepts underlying the complicated mathematics and biostatistics of a pharmacokinetic model of drug handling by the body.
SCOPE Ac{D FUNCTIOX OF CUNICAL

PHAR1IACOLOGY
The three major areas of teaching, research and the clinical service role (Prichard and Turner 1971) are totally inter-related. A clinical problem, for example, may form the basis of a new research project and new information gained by such research may be employed in teaching and in more rational use of drugs in therapy.
The teaching role should include seminar, lecture and tutorial activity for medical students, postgraduate medical staff, general practitioners, nursing and paramedical staff and future clinical pharmacologists. The aim should also be to integrate the teaching of clinical pharmacology with that of all other appropriate disciplines. Knowledge imparted should range from the subcellular sites of drug action, to the direct application of therapeutics to the patient. Prescribing a particular drug safely must include an understanding of its toxicology, potential drug interactions, and its characteristics of absorption, distribution, metabolism and excretion under the circumstances of the diseasedisordered physiological state of the patient concerned.
I~esearch must have clinical relevance and is, of necessity, linked with the teaching and clinical service roles. Potential research areas may embrace studies of the pharmacokinetics of drug action in man. Subjects worthy of continuing investigation include the effects of disease on such parameters as biological halflife, volume of distribution and clearance of drugs. Plasma protein binding performed at 37°C and its relevance to the measurement of the free (pharmacologically active) form of drug and the significance of red cell/plasma partition of drug are areas which require further elucidation. In addition, topics such as drug interactions, adverse drug reactions, clinical trials, genetic aspects of drug metabolism, bioavailability of drugs and various problems of biostatistics, all constitute valid lines of research. The importance of the multidisciplinary approach to research is stressed, with the clinical pharmacologist working in conjunction with and aided by the expertise of various other investigators such as other clinicians, pharmacologists, pharmacists and organic chemists.
The clinical service role involves direct patient responsibility so that the clinical pharmacologist must demonstrate clinical as well as scientific competence. Dissemination of drug information, drug monitoring programmes and the investigation of adverse drug reactions constitute important services which he may provide. In addition, the measurement in selected patients of plasma drug levels in conjunction with plasma protein binding (at 37°C), is a useful adjunct to therapy. Such plasma levels generally bear a much closer (albeit imperfect) relationship to therapeutic effect than does oral drug dosage.
Other spheres in which the clinical pharmacologist may contribute, include the proper design and conduct of clinical trials. There should be liaison with local Departments of Health, the Federal Department of Health and with the pharmaceutical industry. The further investigation and evaluation of new drug formulations and entities constitute important avenues of exploration. He may also contribute to various planning or regulatory bodies such as hospital drug committees, or other committees which are concerned with various aspects of drug treatment in the community.
The potential role of the clinical pharmacologist encompasses a broad field and the foregoing statements are not meant to imply that anyone person should, or in fact could, become significantly involved in all of the areas outlined. Such involvement would depend on many factors including the availability and adequacy of existing services. In addition, there are many regions of therapeutics which are being very efficiently managed by the particular specialty concerned. The discipline of anaesthesia is one such specialty and the remainder of this paper examines the close relationship of anaesthesia to clinical pharmacology.
ANAESTHESIA AND CLINICAL PHARMACOLOGY
Having delineated the ubiquitous role of the clinical pharmacologist, it is obvious that many anaesthetists participate in activities which can be clearly identified with clinical pharmacology (Goldberg 1971 ) and a closer relationship between the disciplines of anaesthesia and clinical pharmacology has been advocated (Crout 1971 , Moyer 1971 , Goldberg 1971 . Anaesthetists are also in a fortunate position as their training programmes emphasize basic pharmacological principles and rational therapeutics. Thus, while the day to day pattern of work of the clinical pharmacologist differs substantially from that of the anaesthetist, both have much in common in their mutual interest in drugs and their safe and effective usage.
The establishment of more academic departments of clinical pharmacology in Australia will ideally occur jointly or at least in close collaboration with departments of pharmacology. The strong base in pharmacology is essential for a proper understanding of drugs (Carr 1971) and the close association with basic scientists has much to offer in terms of expertise and training opportunities. If the view is generally accepted that such departments of clinical pharmacology be multidisciplinary in nature, then the anaesthetist with appropriate training is in a position to make a unique contribution to the various integrated research and education programmes. Apart from being the obvious person for the undergraduate and postgraduate teaching of anaesthetic drugs, toxicology or drug overdosage, he would also participate in the other teaching areas which involve his particular fields of interest, whether these relate to metabolism for example, or any other pharmacological aspect. The clinical pharmacologist could in turn also usefully participate in the various anaesthetic training programmes so that teaching is one aspect of mutual benefit for the two disciplines.
Interdepartmental seminars could add considerable impetus to a stimulating postgraduate programme in therapeutics for members of both anaesthetic and clinical pharmacology departments. The trial attachment of anaesthetists in training to departments of clinical pharmacology for a six to twelve month term for example, could also be of benefit to both disciplines. Similarly, clinical pharmacologists in training could be seconded for suitable periods of time to anaesthetic departments so that more practical knowledge of anaesthesia could be made available to them.
From the research point of view, the amalgamation of the anaesthetist and clinical pharmacologist provides a potentially strong form of expertise which can be applied both to anaesthetic and non-anaesthetic research ventures. Anaesthetists, of course, have for many years carried out studies of anaesthetic drugs in man. Yet a collaborative approach to such investigations can be advantageous both for the anaesthetist and clinical pharmacologist. Access of the clinical pharmacologist to patient problems in anaesthesia and intensive care situations provides him with material with which he would not normally come into contact. Conversely, he may benefit the anaesthetist in terms for example, of advice regarding experimental design and measurement techniques, data analysis and the proper design and management of clinical trials. In regard to such clinical trials, this multi disciplinary investigative team also acts as a safety measure for the patient so that trial protocols may be evaluated more precisely for subtle dangers by the different members of the team. Access of the anaesthetist to advanced pharmacological techniques, measuring equipment and data analysis in the pharmacological laboratory considerably widens the spectrum of his research activities.
The clinical service functions of the anaesthetist and clinical pharmacologist vary in as much as their patient populations differ. Anaesthetists, with their selective populations of preoperative, operative and postoperative patients and those in the intensive care situation, have effectively been practising clinical pharmacology and rational therapeutics in their respective field for many years. In this respect, therefore, as well as the aspects of research and teaching, the anaesthetist has already made significant contributions to the discipline of clinical pharmacology, and clinical pharmacologists in Australia should recognize this fact. A closer relationship between the disciplines of anaesthesia and clinical pharmacology has the potential to provide a stronger basis for the safe and rational use of drugs in man.
